Euro-celtique S.a.

Harm Reduction Therapeutics, Inc.

Purdue Pharma L.p.

Lts Lohmann Therapie-systeme Ag

Mundipharma Laboratories Gmbh

Kevin John Smith

Derek Allan Prater

Stewart Thomas Leslie

Ronald Brown Miller

Alexander Oksche

Horst Winkler

Udo Hahn

Walter Wimmer

Sandra Therese Malkowska

Sandra Therese Antoinette Malkowska

Trevor John Knott

Joanne Heafield

Lucie Helene Jeanne Mottier

John Strang

Stephen Harris

Thomas Hille

Malcolm Walden

Hassan Mohammad

Gabriel Wauer

John Watkins

Gillian Elizabeth Mundin

Helen Elizabeth Johnson

Vanessa Addison

Bernard Kennedy

Will Heath

Paul Bailey

Heikki Mansikka

Stuart Thomas Leslie

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to &#x2265;0.5 mg naloxone HCl dissolved in an application fluid of a volume of &#x2264;250 &#x3bc;l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Intranasal pharmaceutical dosage forms comprising naloxone

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to &#x2265;0.5 mg naloxone HC dissolved in an application fluid of a volume of &#x2264;250 &#x3bc;l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

The present invention provides a method of providing pain relief in a human subject in need thereof comprising administering (R)-dihydroetorphine to said subject, wherein said (R)-dihydroetorphine is administered in a dose of at least 0.01 &#x3bc;g/kg, preferably at least 0.05 &#x3bc;g/kg, and the level of respiratory depression in said subject is 65 or less % relative to the baseline level pre-administration of (R)-dihydroetorphine.

Dihydroetorphine for the provision of pain relief and anaesthesia

The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.

Opioid composition for treating skin lesions

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising

Transdermal delivery system comprising buprenorphine

A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Controlled release tramadol tramadol formulation

Controlled release formulation

Controlled release tramadol

Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35 to 150.degree. C.

Sustained release compositions and a method of preparing pharmaceutical

Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35.degree. to 150.degree. C.

Sustained release compositions of morphine and a method of preparing

Growing community of inventors

Cambridge, United Kingdom

Kevin John Smith